ZYVERSA THERAPEUTICS, INC. Preferred Stock Dividends, Income Statement Impact
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Preferred Stock Dividends, Income Statement Impact of $7.95 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2025-03-27
- ZYVERSA THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2023-12-31 was $0.00.
- ZYVERSA THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2023-09-30 was $32.37K.
- ZYVERSA THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2023-06-30 was $7.92M.
- ZYVERSA THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2023 was $7.95M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 11 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $32.37K derived: sum of 2 quarters · filed 2025-03-27 | $7.95M derived: sum of 3 quarters · filed 2025-03-27 | $7.95M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $32.37K 10-Q · filed 2024-11-14 | $7.95M derived: sum of 2 quarters · filed 2024-11-14 | $7.95M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $7.92M 10-Q · filed 2024-08-09 | $7.92M 10-Q · filed 2024-08-09 | |||
| 2022-12-12 | $10.02M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |